Comments on the new analysis of the Chingleput BCG trial

Indian Journal of Medical Research

Volumn 123, Issue 2, 2006, Pages 103-106

  Rook, Graham A W ^a   Kim, Louise U ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; GAMMA INTERFERON; INTERLEUKIN 4; PLACEBO;

BCG VACCINATION; CELLULAR IMMUNITY; CLINICAL TRIAL; CYTOKINE RELEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME LINKED IMMUNOSPOT ASSAY; HUMAN; HYPOTHESIS; INDIA; INFECTION RISK; MYCOBACTERIUM AVIUM; MYCOBACTERIUM INTRACELLULARE; MYCOBACTERIUM TUBERCULOSIS; NOTE; REGULATORY T LYMPHOCYTE; RISK REDUCTION; TH1 CELL; TH2 CELL; THORAX RADIOGRAPHY; TUBERCULIN TEST; TUBERCULOSIS; TUBERCULOSIS CONTROL;

BCG VACCINE; CLINICAL TRIALS; HUMANS; INDIA; T-LYMPHOCYTES, REGULATORY; TUBERCULIN TEST; VACCINATION;

EID: 33645466246     PISSN: 09715916     EISSN: 09715916     Source Type: Journal    
DOI: None     Document Type: Note

References (20)

1. Tuberculosis Research Centre (ICMR), Chennai. Fifteen year follow up of trial of BCG vaccines in south India for tuberculosis prevention. Indian J Med Res 1999; 110 : 56-69.
2. Tuberculosis Research Centre (ICMR), Chennai. Influence of sex, age and nontuberculous infection at intake on the efficacy of BCG: re-analysis of 15-year data from a doubleblind randomized control trial in south India. Indian J Med Res 2006; 123 : 119-24.
3. Andersen P, Doherty TM. The success and failure of BCG - implications for a novel tuberculosis vaccine. Nat Rev Microbiol 2005; 3 : 656-62.
4. Hart PD, Sutherland I. BCG and vole bacillus vaccines in the prevention of tuberculosis in adolescence and early adult life. Br Med J 1977; 2 : 293-5.
5. Colditz GA, Berkey CS, Mosteller F, Brewer TF, Wilson ME, Burdick E, et al. The efficacy of bacillus Calmette-Guerin vaccination of newborns and infants in the prevention of tuberculosis: meta-analyses of the published literature. Pediatrics 1995; 96 : 29-35.
6. Hill PC, Brookes RH, Fox A, Fielding K, Jeffries DJ, Jackson-Sillah D, et al. Large-scale evaluation of enzyme-linked immunospot assay and skin test for diagnosis of Mycobacterium tuberculosis infection against a gradient of exposure in The Gambia. Clin Infect Dis 2004; 38: 966-73.
7. O'Garra A, Vieira P. Regulatory T cells and mechanisms of immune system control. Nat Med 2004; 10 : 801-5.
8. Zuany-Amorim C, Sawicka E, Manlius C, Le Moine A, Brunet LR, Kemeny DM, et al. Suppression of airway eosinophilia by killed Mycobacterium vaccae-induced allergen-specific regulatory T-cells. Nat Med 2002; 8: 625-9.
9. Floyd S, Ponnighaus JM, Bliss L, Nkhosa P, Sichali L, Msiska G, et al. Kinetics of delayed-type hypersensitivity to tuberculin induced by bacille Calmette-Guerin vaccination in northern Malawi. J Infect Dis 2002; 186: 807-14.
10. Guld J, Waaler H, Sundaresan TK, Kaufmann PC, ten Dam HG. The duration of BCG-induced tuberculin sensitivity in children, and its irrelevance for revaccination. Results of two 5-year prospective studies. Bull World Health Organ 1968; 39 : 829-36.
11. Black GF, Weir RE, Floyd S, Bliss L, Warndorff DK, Crampin AC, et al. BCG-induced increase in interferongamma response to mycobacterial antigens and efficacy of BCG vaccination in Malawi and the UK: two randomised controlled studies. Lancet 2002; 359 : 1393-401.
12. Guyot-Revol V, Innes JA, Hackforth S, Hinks T, Lalvani A. Regulatory T cells are expanded in blood and disease sites in tuberculosis patients. Am J Respir Crit Care Med 2005. Dec 9; [Epub ahead of print].
13. Jouanguy E, Lamhamedi-Cherradi S, Altare F, Fondaneche MC, Tuerlinckx D, Blanche S, et al. Partial interferongamma receptor 1 deficiency in a child with tuberculoid bacillus Calmette-Guerin infection and a sibling with clinical tuberculosis. J Clin Invest 1997; 100 : 2658-64.
14. de Jong R, Altare F, Haagen IA, Elferink DG, Boer T, van Breda Vriesman PJ, et al. Severe mycobacterial and Salmonella infections in interleukin-12 receptor-deficient patients. Science 1998; 280 : 1435-8.
15. Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001; 345 : 1098-104.
16. Dheda K, Chang J-S, Breen RA, Kim LU, Haddock JA, Huggett JF, et al. In vivo and in vitro studies of a novel cytokine, interleukin-4delta2, in pulmonary tuberculosis. Am J Resp Crit Care Med 2005; 172 : 501-8.
17. Rook G, Dheda K, Zumla A. Do successful tuberculosis vaccines need to be immunoregulatory rather than merely Thl-boosting? Vaccine 2005; 23 : 2115-20.
18. Demissie A, Abebe M, Aseffa A, Rook G, Fletcher H, Zumla A, et al. Healthy individuals that control a latent infection with M. tuberculosis express high levels of Th-1 cytokines and the IL-4 antagonist IL-4δ2. J Immunol 2004; 172 : 6938-43.
19. Rook GA, Dheda K, Zumla A. Immune responses to tuberculosis in developing countries: implications for new vaccines. Nat Rev Immunol 2005; 5 : 661-7.
20. Brandt L, Feino Cunha J, Weinreich Olsen A, Chilima B, Hirsch P, Appelberg R, et al. Failure of the Mycobacterium bovis BCG vaccine: some species of environmental mycobacteria block multiplication of BCG and induction of protective immunity to tuberculosis. Infect Immun 2002; 70 : 672-8.